Kukje Pharma Co Ltd
Kukje Pharma Co., Ltd. engages in manufacturing, importing, exporting, selling, and distributing pharmaceutical products. The company offers pharmaceutical products, including ETC and OTC products, raw materials, intermediates, and side chain products, as well as cosmetics and health care products. Its products include cephalosporins, quinolones, tetracycline, aminoglycosides, macrolides, other a… Read more
Kukje Pharma Co Ltd (002720) - Total Liabilities
Latest total liabilities as of September 2025: ₩84.80 Billion KRW
Based on the latest financial reports, Kukje Pharma Co Ltd (002720) has total liabilities worth ₩84.80 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kukje Pharma Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Kukje Pharma Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Kukje Pharma Co Ltd Competitors by Total Liabilities
The table below lists competitors of Kukje Pharma Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NN Inc
NASDAQ:NNBR
|
USA | $294.04 Million |
|
Alicanto Minerals Ltd
AU:AQI
|
Australia | AU$425.52K |
|
Panama Petrochem Limited
NSE:PANAMAPET
|
India | ₹2.93 Billion |
|
Signature Alliance Group Berhad
KLSE:0360
|
Malaysia | RM193.24 Million |
|
First Bankers Trustshares Inc
OTCQB:FBTT
|
USA | $1.11 Billion |
|
SomnoMed Limited
PINK:SOMNF
|
USA | $34.58 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Kukje Pharma Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kukje Pharma Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kukje Pharma Co Ltd (2011–2024)
The table below shows the annual total liabilities of Kukje Pharma Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩76.00 Billion | -2.95% |
| 2023-12-31 | ₩78.31 Billion | +25.27% |
| 2022-12-31 | ₩62.51 Billion | -12.19% |
| 2021-12-31 | ₩71.20 Billion | -5.23% |
| 2020-12-31 | ₩75.13 Billion | +2.02% |
| 2019-12-31 | ₩73.64 Billion | +27.99% |
| 2018-12-31 | ₩57.54 Billion | -9.91% |
| 2017-12-31 | ₩63.87 Billion | +3.12% |
| 2016-12-31 | ₩61.94 Billion | -9.16% |
| 2015-12-31 | ₩68.18 Billion | +2.29% |
| 2014-12-31 | ₩66.66 Billion | +12.78% |
| 2013-12-31 | ₩59.10 Billion | -0.79% |
| 2012-12-31 | ₩59.57 Billion | -10.85% |
| 2011-12-31 | ₩66.82 Billion | -- |